Methods

Patent metadata

Field	Value
Publication number	US-11058617-B2
Application number	US-201916713732-A
Country	US
Kind code	B2
Filing date	Dec 13, 2019
Priority date	Dec 20, 2018
Publication date	Jul 13, 2021
Grant date	Jul 13, 2021

Abstract

Provided herein are methods of treating one or more symptoms of a gastric disorder in the oral cavity of a subject in need thereof, wherein the method comprises applying to the subject's teeth an oral care composition comprising a basic amino acid in free or salt form, wherein the basic amino acid is arginine (e.g., free form arginine); zinc oxide and zinc citrate; and an orally acceptable carrier.

First claim

What is claimed is:

1. A method of treating one or more symptoms of a gastric disorder in the oral cavity of a subject in need thereof, wherein the method comprises applying to the subject's teeth an oral care composition comprising:
a. a basic amino acid in free or salt form, wherein the basic amino acid is arginine in an amount from 0.1 wt % to 6.0 wt %;
b. zinc oxide and zinc citrate, wherein the zinc oxide is present in an amount from 0.75% by wt. to 1.25% by wt. and the zinc citrate is present in an amount from 0.25% by wt. to 1.0% by wt;
c. an orally acceptable carrier;

wherein the gastric disorder is gastroesophageal reflux disease (GERD); and
wherein the one or more symptoms of the gastric disorder comprise dental erosion due to loss of calcium in the subject's tooth enamel consequent to the presence of gastric acid in the oral cavity.

2. The method according to claim 1 , wherein the oral care composition inhibits or decreases the release of calcium from the subject's tooth enamel.

3. The method according to claim 2 , wherein the inhibition or decrease of the release of calcium in the subject's tooth enamel is relative to a reference standard.

4. The method according to claim 1 , wherein the oral care composition inhibits the release of calcium relative to one or more compositions that do not contain zinc.

5. The method according to claim 1 , wherein the one or more symptoms is that the subject is exposed to gastric acids in the oral cavity during sleep.

6. The method according to claim 1 , wherein the subject is at risk for dental erosion.

7. The method according to claim 6 , wherein the risk for dental erosion is selected from the group consisting of: xerostomia, tooth hypersensitivity, weakened tooth integrity, and tooth discoloration.

8. The method according to claim 1 , wherein the oral care composition comprises:
a. about 1.0% zinc oxide,
b. about 0.5% zinc citrate, and
c. about 1.5% L-arginine.

Assignees

• Colgate Palmolive Co

Inventors

• Manus Lisa
• Stranick Michael
• Wu Donghui

Classifications

• A61P1/04

  for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants · CPC title

• A61P1/02

  Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis · CPC title

• A61P1/00

  Drugs for disorders of the alimentary tract or the digestive system · CPC title

• A61K31/198

  Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00) · CPC title

• A61K33/30

  Zinc; Compounds thereof · CPC title